Dr Shona Francey
Honorary (Fellow)
Centre for Youth Mental Health (Orygen)
70 Scholarly works
3 Projects
HIGHLIGHTS
2025
Journal article
Functional Coupling and Longitudinal Outcome Prediction in First-Episode Psychosis
DOI: 10.1016/j.bpsgos.2025.1005892025
Conference Proceedings
556. Longitudinal cortical thickness changes in first episode psychosis: a triple-blind randomised placebo-controlled mri study
DOI: 10.1093/ijnp/pyaf052.1502025
Journal article
Exploring the Implementation of Cognitive Screening in First-Episode Psychosis Settings: The CogScreen Implementation Study
DOI: 10.1111/eip.700042025
Journal article
Brainwide Anatomical Connectivity and Prediction of Longitudinal Outcomes in Antipsychotic-Naïve First-Episode Psychosis
DOI: 10.1016/j.biopsych.2024.07.0162024
Journal article
An open label pilot trial of low-dose lithium for young people at ultra-high risk for psychosis
DOI: 10.1111/eip.135262023
Journal article
Network-Based Spreading of Gray Matter Changes Across Different Stages of Psychosis
DOI: 10.1001/jamapsychiatry.2023.32932022
Research grants (ARC, NHMRC, MRFF)
Validating Cognitive Screening for First-Episode Psychosis - CogScreen
RECENT SCHOLARLY WORKS
2023
Journal article
Gradients of striatal function in antipsychotic-free first-episode psychosis and schizotypy
DOI: 10.1038/s41398-023-02417-22023
Journal article
Social disadvantage in early psychosis and its effect on clinical presentation and service access, engagement and use
DOI: 10.1016/j.psychres.2023.1154782023
Journal article
Correlates of substance use in a large naturalistic cohort of young people with early and emerging psychosis
DOI: 10.1007/s00127-023-02436-w2023
Journal article
Isolating the impact of antipsychotic medication on metabolic health: Secondary analysis of a randomized controlled trial of antipsychotic medication versus placebo in antipsychotic medication naïve first-episode psychosis (the STAGES study)
DOI: 10.1111/eip.13353
RECENT PROJECTS
2014
Research Grant
Antipsychotic Medication in First-Episode Psychosis: An RCT to Assess the Risk-Benefit Ratio
2008
Research Grant
RCT of Omega-3 Fatty Acids as Treatment of Subthreshold Symptoms in Young People at Ultra-High Risk for Psychosis